Therapeutic bispecific antibody formats: a patent applications review (1994-2017)

References

• Ecker DM , Jones SD , Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9–14.
   PubMed Web of Science ®Google Scholar
• Henry H. Therapeutic monoclonal antibodies approved by FDA in 2015. MOJ Immunol. 2016;3:15406.
   Google Scholar
• Alexander PB , Chen R , Gong C , et al. Distinct receptor tyrosine kinase subsets mediate anti-HER2 drug resistance in breast cancer. J Biol Chem. 2017;292:748–759.
   PubMed Web of Science ®Google Scholar
• Klein C , Sustmann C , Thomas M , et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs. 2012;4:653–663.
   PubMed Web of Science ®Google Scholar
• Brinkmann U , Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9:182–212.
   PubMed Web of Science ®Google Scholar
• Van Spriel AB , van Ojik HH , van de Winkel JG . Immunotherapeutic perspective for bispecific antibodies. Immunol Today. 2000;21:391–397.
   PubMedGoogle Scholar
• Kitazawa T , Igawa T , Sampei Z , et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570–1574.
   PubMed Web of Science ®Google Scholar
• Stanimirovic D , Kemmerich K , Haqqani AS , et al. Chapter ten-engineering and pharmacology of blood–brain barrier-permeable bispecific antibodies. Adv Pharmacol. 2014;71:301–335.
   PubMedGoogle Scholar
• Kontermann R . Dual targeting strategies with bispecific antibodies. MAbs. 2012;4:182–197.
   PubMed Web of Science ®Google Scholar
• Spiess C , Zhai Q , Carter PJ . Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:95–106.
   PubMed Web of Science ®Google Scholar
• Fischer N , Léger O . Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology. 2007;74:3–14.
   PubMed Web of Science ®Google Scholar
• Frankel SR , Baeuerle PA . Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013;17:385–392.
   PubMed Web of Science ®Google Scholar
• Lindhofer H , Mocikat R , Steipe B , et al. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol. 1995;155:219–225.
   PubMed Web of Science ®Google Scholar
• Hay M , Thomas DW , Craighead JL , et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51.
   PubMed Web of Science ®Google Scholar
• Storz U . Intellectual property protection: strategies for antibody inventions. MAbs. 2011;3:310–317.
   PubMed Web of Science ®Google Scholar
• Mullard A . FDA approves first bispecific. Nat Rev Drug Discov. 2015;14:7.
   Web of Science ®Google Scholar
• Ishiguro T , Kinoshita Y , Sano Y , et al. Abstract DDT01-05: first-in-class T cell-redirecting bispecific antibody targeting glypican-3: a highly tumor-selective antigen. AACR. 2016.
   Google Scholar
• Chakravarthy U , Bailey C , Brown D , et al. Phase 1 trial of anti–vascular endothelial growth factor/antiangiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. Ophthalmol Retina. 2017;1:474–485.
   PubMedGoogle Scholar
• Bacac M , Fauti T , Sam J , et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22:3286–3297.
   PubMed Web of Science ®Google Scholar
• Brünker P , Wartha K , Friess T , et al. RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven DR5 hyperclustering and tumor cell apoptosis. Mol Cancer Ther. 2016;15(5):946–957.
   PubMed Web of Science ®Google Scholar
• Bacac M , Umaña P , Herter S , et al. CD20 Tcb (RG6026), a novel “2: 1” T cell bispecific antibody for the treatment of B cell malignancies. Blood. 2016;128:1836.
   Web of Science ®Google Scholar
• Van Loo PF , Doornbos R , Dolstra H , et al. Preclinical evaluation of MCLA117, a CLEC12AxCD3 bispecific antibody efficiently targeting a novel leukemic stem cell associated antigen in AML. Blood. 2015;123:325.
   Google Scholar
• DiGiandomenico A , Keller AE , Gao C , et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6:262ra155.
   PubMed Web of Science ®Google Scholar
• Jefferis R , Lund J , Pound JD . IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev. 1998;163:59–76.
   PubMed Web of Science ®Google Scholar
• Kuo TT , Aveson VG . Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011;3:422–430.
   PubMed Web of Science ®Google Scholar
• Tustian AD , Endicott C , Adams B , et al. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. MAbs. 2016;8:828–838.
   PubMed Web of Science ®Google Scholar
• Van Der Neut Kolfschoten M , Schuurman J , Losen M , et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317:1554–1557.
   PubMed Web of Science ®Google Scholar
• Köhler G , Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497.
   PubMed Web of Science ®Google Scholar
• Zeidler R , Reisbach G , Wollenberg B , et al. Simultaneous activation of t cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999;163:1246–1252.
   PubMed Web of Science ®Google Scholar
• Chames P , Van Regenmortel M , Weiss E , et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220–233.
   PubMed Web of Science ®Google Scholar
• Heiss MM , Murawa P , Koralewski P , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127:2209–2221.
   PubMed Web of Science ®Google Scholar
• Ridgway JB , Presta LG , Carter P . ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel. 1996;9:617–621.
   Google Scholar
• Merchant AM , Zhu Z , Yuan JQ , et al. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16:677–681.
   PubMed Web of Science ®Google Scholar
• Schaefer W , Regula JT , Bähner M , et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA. 2011;108:11187–11192.
   PubMed Web of Science ®Google Scholar
• Klein C , Schaefer W , Regula JT . The use of CrossMAb technology for the generation of bi-and multispecific antibodies. MAbs. 2016;8:1010–1020.
   PubMed Web of Science ®Google Scholar
• Bendell JC , Sauri T , Cubillo A , et al. Final results of the McCAVE trial: a double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC). ASCO. 2017.
   Google Scholar
• Igawa T , Tsunoda H , Kuramochi T , et al. Engineering the variable region of therapeutic IgG antibodies. MAbs. 2011;3:243–252.
   PubMed Web of Science ®Google Scholar
• Jimeno A , Moore K , Gordon M , et al. A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors. Eur J Cancer. 2016;69:S35.
   Web of Science ®Google Scholar
• Oldenburg J , Mahlangu JN , Kim B , et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–818.
   PubMed Web of Science ®Google Scholar
• Smith EJ , Olson K , Haber LJ , et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. 2015;5:17943.
   PubMed Web of Science ®Google Scholar
• Klooster R , Geuijen C , Throsby M . Abstract B088: generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity. AACR. 2016.
   Google Scholar
• Calvo E , Alsina M , Schellens JHM , et al. Abstract CT050: a Phase I/II Study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3, in patients with solid tumors. Cancer Res. 2016;76:CT050.
   Web of Science ®Google Scholar
• Von Kreudenstein TS , Escobar-Carbrera E , Lario PI , et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs. 2013;5:646–654.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F , Beeram M , Blum MA , et al. Phase 1 dose escalation of ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers. ASCO. 2017.
   Google Scholar
• Moore GL , Bautista C , Pong E , et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs. 2011;3:546–557.
   PubMed Web of Science ®Google Scholar
• Chu SY , Pong E , Chen H , et al. Immunotherapy with long-lived anti-CD123× anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia. Am Soc Hematol. 2014;124:2316.
   Google Scholar
• Labrijn AF , Buijsse AO , Van Den Bremer ET , et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27:767–771.
   PubMed Web of Science ®Google Scholar
• Labrijn AF , Meesters JI , De Goeij BECG , et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA. 2013;110:5145–5150.
   PubMed Web of Science ®Google Scholar
• Grugan KD , Dorn K , Jarantow SW , et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs. 2017;9:114–126.
   PubMed Web of Science ®Google Scholar
• Gaudet F , Nemeth JF , McDaid R , et al. Development of a CD123xCD3 bispecific antibody (JNJ-63709178) for the treatment of acute myeloid leukemia (AML). Am Soc Hematol. 2016.
   Google Scholar
• Moretti P , Skegro D , Ollier R , et al. BEAT® the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs. BMC Proc. 2013;7:O9.
   Google Scholar
• Skegro D , Stutz C , Ollier R , et al. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. J Biol Chem. 2017;292:9745–9759.
   PubMed Web of Science ®Google Scholar
• Croset A , Macoin J , Ollier R , et al. 139 GBR1302: a BEAT® bispecific antibody for the treatment of HER2 positive cancers. Eur J Cancer. 2014;50:48.
   Web of Science ®Google Scholar
• Wu C , Ying H , Grinnell C , et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007;25:1290–1297.
   PubMed Web of Science ®Google Scholar
• Correia I , Sung J , Burton R , et al. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. MAbs. 2013;5:364–372.
   PubMed Web of Science ®Google Scholar
• Jakob CG , Edalji R , Judge RA , et al. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule. MAbs. 2013;5:358–363.
   PubMed Web of Science ®Google Scholar
• Kosloski MP , Goss S , Wang SX , et al. Pharmacokinetics and tolerability of a dual variable domain immunoglobulin ABT‐981 against IL‐1α and IL‐1β in healthy subjects and patients with osteoarthritis of the knee. J Clin Pharmacol. 2016;56:1582–1590.
   PubMed Web of Science ®Google Scholar
• Gordon MS , Nemunaitis JJ , Ramanathan RK , et al. Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors. ASCO. 2016.
   Google Scholar
• Khatri A , Goss S , Jiang P , et al. Pharmacokinetics of ABT-122, a TNF-α-and IL-17A-targeted dual-variable domain immunoglobulin, in healthy subjects and patients with rheumatoid arthritis: results from three phase I trials. Clin Pharmacokinet. 2017;1–11.
   PubMed Web of Science ®Google Scholar
• Rao E , Li D , Underwood S , et al. Generation of a tetravalent bispecific antibody against IL4 and IL13 for the treatment of idiopathic pulmonary fibrosis. MAbs. 2011;4:14–16.
   Google Scholar
• Ko AH , Murray J , Horgan KE , et al. A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC). ASCO. 2016.
   Google Scholar
• Liu L , Zeng W , Chedid M , et al. A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance. AACR. 2016.
   Google Scholar
• Li J , Toader D , Perry SR , et al. MEDI4276, a HER2-targeting antibody tubulysin conjugate, displays potent in vitro and in vivo activity in preclinical studies. AACR. 2016.
   Google Scholar
• Schlatter D , Brack S , Banner DW , et al. Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. MAbs. 2012;4:497–508.
   PubMed Web of Science ®Google Scholar
• Silacci M , Lembke W , Woods R , et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs. 2016;8:141–149.
   PubMed Web of Science ®Google Scholar
• Eigenbrot C , Fuh G . Two-in-One antibodies with dual action Fabs. Curr Opin Chem Biol. 2013;17:400–405.
   PubMed Web of Science ®Google Scholar
• Jimeno A , Machiels JP , Wirth L , et al. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2016;122:3803–3811.
   PubMed Web of Science ®Google Scholar
• Sharkey RM , Rossi EA , McBride WJ , et al. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med. 2010;40:190–203.
   PubMed Web of Science ®Google Scholar
• Rossi EA , Goldenberg DM , Cardillo TM , et al. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood. 2009;113:6161–6171.
   PubMed Web of Science ®Google Scholar
• Faivre-Chauvet A , Carlier T , Rauscher A , et al. Immuno-PET using anti-CEA bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a first-in human trial. J Nucl Med. 2016;57:1505–1511.
   PubMed Web of Science ®Google Scholar
• Strohl WR . Current progress in innovative engineered antibodies. Protein Cell. 2017;1–35.
   PubMed Web of Science ®Google Scholar
• Friedrich M , Raum T , Lutterbuese R , et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther. 2012;11:2664–2673.
   PubMed Web of Science ®Google Scholar
• Hipp S , Tai Y , Blanset D , et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2016;31:2278.
   Web of Science ®Google Scholar
• Laszlo G , Gudgeon C , Harrington K , et al. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood Cancer J. 2015;5:e340.
   PubMed Web of Science ®Google Scholar
• Vanheusden K , Detalle L , Hemeryck A , et al. Abstract number: 1287. Pre-clinical proof-of-concept of Alx-0761, a nanobody® neutralizing both Il-17a and F in a cynomolgus monkey collagen induced arthritis model. Arthritis Rheum. 2013.
   Google Scholar
• Tolcher AW , Alley EW , Chichili G , et al. Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature. ASCO. 2016.
   Google Scholar
• Liu L , Lam C-YK , Long V , et al. MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clin Cancer Res. 2017;23:1506–1518.
   PubMed Web of Science ®Google Scholar
• Pandya N , Chen W , Lohr J , et al. OP0201 safety, tolerability, and functional activity of MGD010, a dart® molecule targeting CD32B and CD79B, following a single dose administration in healthy volunteers. Ann Rheum Dis. 2016;75:132–133.
   Web of Science ®Google Scholar
• LaMotte-Mohs R , Shah K , Smith D , et al. MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment. AACR. 2016.
   Google Scholar
• Root AR , Cao W , Li B , et al. Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer. Antibodies. 2016;5:1–30.
   Web of Science ®Google Scholar
• MacDiarmid JA , Langova V , Bailey D , et al. Targeted doxorubicin delivery to brain tumors via minicells: proof of principle using dogs with spontaneously occurring tumors as a model. PLoS One. 2016;11:e0151832.
   PubMed Web of Science ®Google Scholar
• Vallera DA , Chen H , Sicheneder AR , et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res. 2009;33:1233–1242.
   PubMed Web of Science ®Google Scholar
• Bird RE , Hardman KD , Jacobson JW , et al. Single-chain antigen-binding proteins. Science. 1988;242:423–427.
   PubMed Web of Science ®Google Scholar
• Huston JS , Levinson D , Mudgett-Hunter M , et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA. 1988;85:5879–5883.
   PubMed Web of Science ®Google Scholar
• Holliger P , Prospero T , Winter G . “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA. 1993;90:6444–6448.
   PubMed Web of Science ®Google Scholar
• Alt M , Müller R , Kontermann RE . Novel tetravalent and bispecific IgG‐like antibody molecules combining single‐chain diabodies with the immunoglobulin γ1 Fc or CH3 region. FEBS Lett. 1999;454:90–94.
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM , Moldenhauer G , Schuhmacher J , et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol. 1999;293:41–56.
   PubMed Web of Science ®Google Scholar
• Johnson S , Burke S , Huang L , et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol. 2010;399:436–449.
   PubMed Web of Science ®Google Scholar
• Chichili GR , Huang L , Li H , et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015;7:289ra82–289ra82.
   PubMed Web of Science ®Google Scholar
• Reusch U , Duell J , Ellwanger K , et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells. MAbs. 2015;7:584–604.
   PubMed Web of Science ®Google Scholar
• Wu J , Fu J , Zhang M , et al. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8:96.
   PubMed Web of Science ®Google Scholar
• Przepiorka D , Ko C-W , Deisseroth A , et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21:4035–4039.
   PubMed Web of Science ®Google Scholar
• Oberst MD , Fuhrmann S , Mulgrew K , et al. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs. 2014;6:1571–1584.
   PubMed Web of Science ®Google Scholar
• Hernandez-Hoyos G , Sewell T , Bader R , et al. MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther. 2016;15:2155–2165.
   PubMed Web of Science ®Google Scholar
• Bossi G , Buisson S , Oates J , et al. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother. 2014;63:437–448.
   PubMed Web of Science ®Google Scholar
• Liddy N , Bossi G , Adams KJ , et al. Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012;18:980–987.
   PubMed Web of Science ®Google Scholar
• Taylor K , Howard CB , Jones ML , et al. Nanocell targeting using engineered bispecific antibodies. MAbs. 2015;7:53–65.
   PubMed Web of Science ®Google Scholar
• Kao SC , Fulham M , Wong K , et al. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. Am J Respir Crit Care Med. 2015;191:1467–1469.
   PubMed Web of Science ®Google Scholar
• Reid G , Kao SC , Pavlakis N , et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8:1079–1085.
   PubMed Web of Science ®Google Scholar
• Conrath KE , Lauwereys M , Wyns L , et al. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem. 2001;276:7346–7350.
   PubMed Web of Science ®Google Scholar
• Coppieters K , Dreier T , Silence K , et al. Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis. Arthritis Rheum. 2006;54:1856–1866.
   PubMed Web of Science ®Google Scholar
• Yang F , Wen W , Qin W . Bispecific antibodies as a development platform for new concepts and treatment strategies. Int J Mol Sci. 2016;18:48.
   PubMed Web of Science ®Google Scholar
• Müller D , Karle A , Meißburger B , et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 2007;282:12650–12660.
   PubMed Web of Science ®Google Scholar
• Mukherjee C , Hutmacher A , Peterson M , et al. Pharmacokinetic-pharmacodynamic modeling of ozoralizumab (atn-103), a novel humanized nanobody tumor necrosis factor inhibitor for rheumatoid arthritis. Arthritis Rheumatol. 2011;63:1259.
   Google Scholar
• Van Roy M , Ververken C , Beirnaert E , et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015;17:135.
   PubMed Web of Science ®Google Scholar
• Lahrtz F . How to successfully patent therapeutic antibodies. J Biom Screen. 2015;20:484–491.
   PubMedGoogle Scholar
• Fischer N , Elson G , Magistrelli G , et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun. 2015;6:6113.
   PubMed Web of Science ®Google Scholar
• Davis JH , Aperlo C , Li Y , et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel. 2010;23(4):195–202.
   PubMed Web of Science ®Google Scholar
• Wozniak-Knopp G , Bartl S , Bauer A , et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel. 2010;23:289–297.
   PubMed Web of Science ®Google Scholar